Obesity-Related Hypertension: Pathogenesis, Cardiovascular Risk, and Treatment: A Position Paper of The Obesity Society and the American Society of Hypertension Landsberg et al. Obesity Related Hypertension

Journal of Clinical Hypertension

Volumn 15, Issue 1, 2013, Pages 14-33

  Landsberg, Lewis ^a   Aronne, Louis J ^b   Beilin, Lawrence J ^c   Burke, Valerie ^c   Igel, Leon I ^b   Lloyd Jones, Donald ^a   Sowers, James ^d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d University of Missouri   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANOREXIGENIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; EXENDIN 4; HYDROCHLOROTHIAZIDE; LEPTIN; LINAGLIPTIN; LIRAGLUTIDE; LOOP DIURETIC AGENT; LORCASERIN; METFORMIN; NALTREXONE; NEBIVOLOL; PHENTERAMINE; PHENTERMINE PLUS TOPIRAMATE; PRAMLINTIDE; SAXAGLIPTIN; SITAGLIPTIN; SPIRONOLACTONE; TETRAHYDROLIPSTATIN; THIAZIDE DIURETIC AGENT; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APPETITE; ARTICLE; BARIATRIC SURGERY; BEHAVIOR THERAPY; BLOOD PRESSURE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHILDHOOD DISEASE; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DYSLIPIDEMIA; ENERGY EXPENDITURE; GASTROINTESTINAL TOXICITY; HEART FAILURE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; KIDNEY DISEASE; LIFESTYLE; MALABSORPTION; METABOLIC SYNDROME X; NATRIURESIS; OBESITY; PATHOGENESIS; PHYSICAL ACTIVITY; PHYSICIAN; POPULATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIDE EFFECT; SMOKING; SOCIETY; SODIUM EXCRETION; SODIUM RESTRICTION; SYMPATHETIC TONE; THERMOGENESIS; WEIGHT GAIN; WEIGHT REDUCTION;

ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION; LIFE STYLE; OBESITY; RISK; UNITED STATES;

EID: 84871938490     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12049     Document Type: Article

References (222)

1. American Heart Association, Overweight and Obesity Statistics - 2009 Update. 2009.
2. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA. 2010;303:235-241.
3. Pickering G. High Blood Pressure. New York, NY: Grune and Stratton, Inc; 1968.
4. Kannel WB, Brand N, Skinner JJ Jr, et al.The relation of adiposity to blood pressure and development of hypertension. The Framingham study. Ann Intern Med. 1967;67:48-59.
5. Vague J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr. 1956;4:20-34.
6. Lapidus L, Bengtsson C, Larsson B, et al.Distribution of adipose tissue and risk of cardiovascular disease and death: a 12year follow up of participants in the population study of women in Gothenburg, Sweden. Br Med J (Clin Res Ed). 1984;289:1257-1261.
7. Larsson B, Svardsudd K, Welin L, et al.Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13year follow up of participants in the study of men born in 1913. Br Med J (Clin Res Ed). 1984;288:1401-1404.
8. Cassano PA, Segal MR, Vokonas PS, Weiss ST. Body fat distribution, blood pressure, and hypertension. A prospective cohort study of men in the normative aging study. Ann Epidemiol. 1990;1:33-48.
9. Kissebah AH, Vydelingum N, Murray R, et al.Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab. 1982;54:254-260.
10. Krotkiewski M, Bjorntorp P, Sjostrom L, Smith U. Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution. J Clin Invest. 1983;72:1150-1162.
11. Kalkhoff RK, Hartz AH, Rupley D, et al.Relationship of body fat distribution to blood pressure, carbohydrate tolerance, and plasma lipids in healthy obese women. J Lab Clin Med. 1983;102:621-627.
12. Ferrannini E, Buzzigoli G, Bonadonna R, et al.Insulin resistance in essential hypertension. N Engl J Med. 1987;317:350-357.
13. Modan M, Halkin H, Almog S, et al.Hyperinsulinemia. A link between hypertension obesity and glucose intolerance. J Clin Invest. 1985;75:809-817.
14. Landsberg L. The metabolic syndrome: diabetes, obesity and hypertension. In: Birkenager WH, Robertson JIS, Zanchetti A, eds. Handbook of Hypertension. Hypertension in the Twentieth Century: Concepts and Achievements. Vol 22. Elsevier: Amsterdam; 2004:245-261.
15. Landsberg L. Insulin-mediated sympathetic stimulation: role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why). J Hypertens. 2001;19(3 Pt 2):523-528.
16. Rowe JW, Young JB, Minaker KL, et al.Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes. 1981;30:219-225.
17. Hausberg M, Mark AL, Hoffman RP, et al.Dissociation of sympathoexcitatory and vasodilator actions of modestly elevated plasma insulin levels. J Hypertens. 1995;13:1015-1021.
18. Troisi RJ, Weiss ST, Parker DR, et al.Relation of obesity and diet to sympathetic nervous system activity. Hypertension. 1991;17:669-677.
19. Grassi G, Seravalle G, Cattaneo BM, et al.Sympathetic activation in obese normotensive subjects. Hypertension. 1995;25:560-563.
20. Scherrer U, Randin D, Tappy L, et al.Body fat and sympathetic nerve activity in healthy subjects. Circulation. 1994;89:2634-2640.
21. Grassi G, Seravalle G, Colombo M, et al.Body weight reduction, sympathetic nerve traffic, and arterial baroreflex in obese normotensive humans. Circulation. 1998;97:2037-2042.
22. DeFronzo RA. Insulin and renal sodium handling: clinical implications. Int J Obes (Lond). 1981;5(suppl 1):93-104.
23. Kennedy A, Gettys TW, Watson P, et al.The metabolic significance of leptin in humans: gender-based differences in relationship to adiposity, insulin sensitivity, and energy expenditure. J Clin Endocrinol Metab. 1997;82:1293-1300.
24. Tang-Christensen M, Havel PJ, Jacobs RR, et al.Central administration of leptin inhibits food intake and activates the sympathetic nervous system in rhesus macaques. J Clin Endocrinol Metab. 1999;84:711-717.
25. Haynes WG, Morgan DA, Walsh SA, et al.Receptor-mediated regional sympathetic nerve activation by leptin. J Clin Invest. 1997;100:270-278.
26. Mantzoros CS. The role of leptin in human obesity and disease: a review of current evidence. Ann Intern Med. 1999;130:671-680.
27. Shek EW, Brands MW, Hall JE. Chronic leptin infusion increases arterial pressure. Hypertension. 1998;31:409-414.
28. Dunbar JC, Hu Y, Lu H. Intracerebroventricular leptin increases lumbar and renal sympathetic nerve activity and blood pressure in normal rats. Diabetes. 1997;46:2040-2043.
29. Agata J, Masuda A, Takada M, et al.High plasma immunoreactive leptin level in essential hypertension. Am J Hypertens. 1997;10(10 Pt 1):1171-1174.
30. Kazumi T, Kawaguchi A, Katoh J, et al.Fasting insulin and leptin serum levels are associated with systolic blood pressure independent of percentage body fat and body mass index. J Hypertens. 1999;17:1451-1455.
31. Landsberg L. Diet, obesity and hypertension: an hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis. Q J Med. 1986;61:1081-1090.
32. Engeli S, Bohnke J, Gorzelniak K, et al.Weight loss and the renin-angiotensin-aldosterone system. Hypertension. 2005;45:356-362.
33. Goodfriend TL. Obesity, sleep apnea, aldosterone, and hypertension. Curr Hypertens Rep. 2008;10:222-226.
34. Sarzani R, Salvi F, Dessi-Fulgheri P, Rappelli A. Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans. J Hypertens. 2008;26:831-843.
35. Bomback AS, Klemmer PJ. Interaction of aldosterone and extracellular volume in the pathogenesis of obesity-associated kidney disease: a narrative review. Am J Nephrol. 2009;30:140-146.
36. Bogaert YE, Linas S. The role of obesity in the pathogenesis of hypertension. Nat Clin Pract Nephrol. 2009;5:101-111.
37. Ahmed SB, Fisher ND, Stevanovic R, Hollenberg NK. Body mass index and angiotensin-dependent control of the renal circulation in healthy humans. Hypertension. 2005;46:1316-1320.
38. Hall JE, Guyton AC, Coleman TG, et al.Regulation of arterial pressure: role of pressure natriuresis and diuresis. Fed Proc. 1986;45:2897-2903.
39. Rocchini AP, Key J, Bondie D, et al.The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N Engl J Med. 1989;321:580-585.
40. Adamczak M, Wiecek A, Funahashi T, et al.Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens. 2003;16:72-75.
41. Van Cauter SK. Sleep as a mediator of the relationship between socioeconomic status and health: a hypothesis. Annals N Y Acad Sci. 1999;896:254-261.
42. Narkiewicz K, Somers VK. Sympathetic nerve activity in obstructive sleep apnoea. Acta Physiol Scand. 2003;177:385-390.
43. Wolk R, Shamsuzzaman AS, Somers VK. Obesity, sleep apnea, and hypertension. Hypertension. 2003;42:1067-1074.
44. Spiegel K, Leproult R, L'Hermite-Baleriaux M, et al.Leptin levels are dependent on sleep duration: relationships with sympathovagal balance, carbohydrate regulation, cortisol, and thyrotropin. J Clin Endocrinol Metab. 2004;89:5762-5771.
45. Barker DJ. Fetal programming of coronary heart disease. Trends Endocrinol Metab. 2002;13:364-368.
46. Silverman BL, Landsberg L, Metzger BE. Fetal hyperinsulinism in offspring of diabetic mothers. Association with the subsequent development of childhood obesity. Ann N Y Acad Sci. 1993;699:36-45.
47. Hausberg M, Barenbrock M, Kosch M. Elevated sympathetic nerve activity: the link between low birth size and adult-onset metabolic syndrome?J Hypertens. 2004;22:1087-1089.
48. Caballero AE. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes Res. 2003;11:1278-1289.
49. Barrett EJ, Eggleston EM, Inyard AC, et al.The vascular actions of insulin control its delivery to muscle and regulate the rate-limiting step in skeletal muscle insulin action. Diabetologia. 2009;52:752-764.
50. Gillespie C, Kuklina EV, Briss PA, et al.Vital signs: prevalence, treatment, and control of hypertension: United States, 1999-2002 and 2005-2008. MMWR Morb Mortal Wkly Rep. 2011;60:103-108.
51. Roger VL, Go AS, Lloyd-Jones DM, et al.Heart disease and stroke statistics - 2011 update: a report from the American Heart Association. Circulation. 2011;123:e18-e209.
52. Wang Y, Wang QJ. The prevalence of prehypertension and hypertension among US adults according to the new Joint National Committee guidelines. Arch Intern Med. 2004;164:2126-2134.
53. Wilson PWF, D'Agostino RB, Sullivan L, et al.Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 2002;162:1867-1872.
54. Burt VL, Whelton P, Roccella EJ, et al.Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995;25:305-313.
55. Franklin SS, Gustin W, Wong ND, et al.Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation. 1997;96:308-315.
56. Lloyd-Jones DM, Liu K, Colangelo LA, et al.Consistently stable or decreased body mass index in young adulthood and longitudinal changes in metabolic syndrome components: the Coronary Artery Risk Development in Young Adults Study. Circulation. 2007;115:1004-1011.
57. Mamun AA, Lawlor DA, O'Callaghan MJ, et al.Effect of body mass index changes between ages 5 and 14 on blood pressure at age 14: findings from a birth cohort study. Hypertension. 2005;45:1083-1087.
58. Collaboration PS. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
59. Neaton JD, Kuller L, Stamler J, Wentworth DN. Impact of systolic and diastolic blood pressure on cardiovascular mortality. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, and Management, 2nd ed. New York, NY: Raven Press; 1995:127-144.
60. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med. 1993;153:598-615.
61. Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA. 2005;294:466-472.
62. Lloyd-Jones DM, Evans JC, Larson MG, et al.Cross-classification of JNC VI blood pressure stages and risk groups in the Framingham Heart Study. Arch Intern Med. 1999;159:2206-2212.
63. D'Agostino RB, Grundy SM, Sullivan LM, et al.Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001;286:180-187.
64. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:8:983-8.
65. Seshadri S, Beiser A, Kelly-Hayes M, et al.The lifetime risk of stroke: estimates from the Framingham Study. Stroke. 2006;37:345-350.
66. Wolf P, D'Agostino R, Belanger A, Kannel W. Probability of stroke: a risk profile from the Framingham Study. Stroke. 1991;22:312-318.
67. Lloyd-Jones DM, Larson MG, Leip EP, et al.Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002;106:3068-3072.
68. Levy D, Larson MG, Vasan RS, et al.The progression from hypertension to congestive heart failure. JAMA. 1996;275:1557-1562.
69. Hsu C-Y, McCulloch CE, Darbinian J, et al.Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med. 2005;165:923-928.
70. Hsu CY, McCulloch CE, Iribarren C, et al.Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006;144:21-28.
71. Stamler J, Dyer AR, Shekelle RB, et al.Relationship of baseline major risk factors to coronary and all-cause mortality, and to longevity: findings from long-term follow-up of Chicago cohorts. Cardiology. 1993;82:191-222.
72. Sever PS, Dahlof B, Poulter NR, et al.Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-1158.
73. Hansson L, Zanchetti A, Carruthers SG, et al.Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755-1762.
74. Haffner SM, Lehto S, Ronnemaa T, et al.Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-234.
75. Juutilainen A, Lehto S, Ronnemaa T, et al.Type 2 diabetes as a "coronary heart disease equivalent": an 18-year prospective population-based study in Finnish subjects. Diabetes Care. 2005;28:2901-2907.
76. Hansen BC, Bray GA. The Metabolic Syndrome Epidemiology, Clinical Treatment, and Underlying Mechanisms. Totowa, NJ: Humana Press; 2008.
77. Reaven GM. Metabolic Syndrome To Be or Not to Be? In: Hansen BC, Bray GA, eds. The Metabolic Syndrome Epidemiology, Clinical Treatment, and Underlying Mechanisms. Totowa, NJ: Humana Press; 2008:11-36.
78. Ervin R. Prevalence of metabolic syndrome among adults 20years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003-2006. Natl Health Stat Reports. 2009;13:1-8.
79. Grundy SM, Brewer HB Jr, Cleeman JI, et al.Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433-438.
80. Sanchez-Lozada LG, Tapia E, Jimenez A, et al.Fructose-induced metabolic syndrome is associated with glomerular hypertension and renal microvascular damage in rats. Am J Physiol Renal Physiol. 2007;292:F423-F429.
81. Lee JE, Kim YG, Choi YH, et al.Serum uric acid is associated with microalbuminuria in prehypertension. Hypertension. 2006;47:962-967.
82. Johnson RJ, Segal MS, Sautin Y, et al.Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. Am J Clin Nutr. 2007;86:899-906.
83. Choi J. Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2008;59:109-116.
84. Spiegel K, Leproult R, Van Cauter E. Impact of sleep debt on metabolic and endocrine function. Lancet. 1999;354:1435-1439.
85. Bass J, Turek FW. Sleepless in America: a pathway to obesity and the metabolic syndrome?Arch Intern Med. 2005;165:15-16.
86. Turek FW, Joshu C, Kohsaka A, et al.Obesity and metabolic syndrome in circadian Clock mutant mice. Science. 2005;308:1043-1045.
87. Nedeltcheva AV, Kilkus JM, Imperial J, et al.Insufficient sleep undermines dietary efforts to reduce adiposity. Ann Intern Med. 2010;153:435-441.
88. l'Allemand-Jander D. Clinical diagnosis of metabolic and cardiovascular risks in overweight children: early development of chronic diseases in the obese child. Int J Obes (Lond). 2010;34(suppl 2):S32-S36.
89. Srinivasan SR, Myers L, Berenson GS. Changes in metabolic syndrome variables since childhood in prehypertensive and hypertensive subjects: the Bogalusa Heart Study. Hypertension. 2006;48:33-39.
90. Juonala M, Magnussen CG, Berenson GS, et al.Childhood adiposity, adult adiposity, and cardiovascular risk factors. N Engl J Med. 2011;365:1876-1885.
91. Craigie AM, Lake AA, Kelly SA, et al.Tracking of obesity-related behaviours from childhood to adulthood: a systematic review. Maturitas. 2011;70:266-284.
92. Eriksson J, Forsen T, Tuomilehto J, et al.Fetal and childhood growth and hypertension in adult life. Hypertension. 2000;36:790-794.
93. Huang RC, Mori TA, Burke V, et al.Synergy between adiposity, insulin resistance, metabolic risk factors, and inflammation in adolescents. Diabetes Care. 2009;32:695-701.
94. Huang RC, Burke V, Newnham JP, et al.Perinatal and childhood origins of cardiovascular disease. Int J Obes (Lond). 2007;31:236-244.
95. Chivers PT, Hands B, Parker H, et al.Longitudinal modelling of body mass index from birth to 14years. Obes Facts. 2000;2:302-310.
96. Waters E, de Silva-Sanigorski A, Hall BJ, et al.Interventions for preventing obesity in children. Cochrane Database Syst Rev. 2011;12:CD001871.
97. Vandongen R, Jenner DA, Thompson C, et al.A controlled evaluation of a fitness and nutrition intervention program on cardiovascular health in 10- to 12-year-old children. Prev Med. 1995;24:9-22.
98. Burke V, Milligan RA, Thompson C, et al.A controlled trial of health promotion programs in 11-year-olds using physical activity "enrichment" for higher risk children. J Pediatr. 1998;132:840-848.
99. Milligan RA, Thompson C, Vandongen R, et al.Clustering of cardiovascular risk factors in Australian adolescents: association with dietary excesses and deficiencies. J Cardiovasc Risk. 1995;2:515-523.
100. Taylor BJ, Heath AL, Galland BC, et al.Prevention of Overweight in Infancy (POI.nz) study: a randomised controlled trial of sleep, food and activity interventions for preventing overweight from birth. BMC Public Health. 2011;11:942.
101. Berenson GS. Cardiovascular health promotion for children: a model for a Parish (County)-wide program (implementation and preliminary results). Prev Cardiol. 2010;13:23-28.
102. Sobko T, Svensson SV, Ek A, et al.A randomised controlled trial for overweight and obese parents to prevent childhood obesity-Early STOPP (Stockholm Obesity Prevention Program). BMC Public Health. 2011;11:336.
103. Christie D, Hudson L, Mathiot A, et al.Assessing the efficacy of the healthy eating and lifestyle programme (HELP) compared with enhanced standard care of the obese adolescent in the community: study protocol for a randomized controlled trial. Trials. 2011;12:242.
104. Borys JM, Le Bodo Y, Jebb SA, et al.EPODE approach for childhood obesity prevention: methods, progress and international development. Obes Rev. 2011;13:299-315.
105. Mozaffarian D, Hao T, Rimm EB, et al.Changes in diet and lifestyle and long-term weight gain in women and men. N Engl J Med. 2011;364:2392-2404.
106. Wang Y, Beydoun MA. The obesity epidemic in the United States - gender, age, socioeconomic, racial/ethnic, and geographic characteristics: a systematic review and meta-regression analysis. Epidemiol Rev. 2007;29:6-28.
107. Popkin BM, Adair LS, Ng SW. Global nutrition transition and the pandemic of obesity in developing countries. Nutr Rev. 2011;70:3-21.
108. Zhai F, Wang H, Wang Z, et al.Closing the energy gap to prevent weight gain in China. Obes Rev. 2008;9(suppl 1):107-112.
109. Akers JD, Estabrooks PA, Davy BM. Translational research: bridging the gap between long-term weight loss maintenance research and practice. J Am Diet Assoc. 2010;110:1511-1522, 22 e1-3.
110. Anderson SE, Whitaker RC. Prevalence of obesity among US preschool children in different racial and ethnic groups. Arch Pediatr Adolesc Med. 2009;163:344-348.
111. Neter JE, Stam BE, Kok FJ, et al.Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2003;42:878-884.
112. Aucott L, Poobalan A, Smith WC, et al.Effects of weight loss in overweight/obese individuals and long-term hypertension outcomes: a systematic review. Hypertension. 2005;45:1035-1041.
113. Aucott L, Rothnie H, McIntyre L, et al.Long-term weight loss from lifestyle intervention benefits blood pressure?: a systematic review. Hypertension. 2009;54:756-762.
114. Siebenhofer A, Jeitler K, Berghold A, et al.Long-term effects of weight-reducing diets in hypertensive patients. Cochrane Database Syst Rev. 2011;9:CD008274.
115. Bray GA. Lifestyle and pharmacological approaches to weight loss: efficacy and safety. J Clin Endocrinol Metab. 2008;93(11 suppl 1):S81-S88.
116. Makris A, Foster GD. Dietary approaches to the treatment of obesity. Psychiatr Clin North Am. 2011;34:813-827.
117. Avenell A, Broom J, Brown TJ, et al.Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess. 2004;8:iii-iv, 1-182.
118. Nordmann AJ, Nordmann A, Briel M, et al.Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. Arch Intern Med. 2006;166:285-293.
119. Appel LJ. ASH position paper: dietary approaches to lower blood pressure. J Am Soc Hypertens. 2009;3:321-331.
120. Appel LJ, Moore TJ, Obarzanek E, et al.A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med. 1997;336:1117-1124.
121. Joint National Committee on Prevention E, and Treatment of High Blood Pressure. The Seventh Report of the Joint National Committee on Prevention, Evaluation, and Treatment of High Blood Pressure. Bethesda, MD: US Department of Health and Human Services; 2004. NIH publication 04-5230.
122. Kastorini CM, Milionis HJ, Esposito K, et al.The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534, 906 individuals. J Am Coll Cardiol. 2011;57:1299-1313.
123. Beilin LJ, Burke V. Vegetarian diet components, protein and blood pressure: which nutrients are important?Clin Exp Pharmacol Physiol. 1995;22:195-198.
124. Miller ER 3rd, Erlinger TP, Young DR, et al.Results of the Diet, Exercise, and Weight Loss Intervention Trial (DEW-IT). Hypertension. 2002;40:612-618.
125. Elmer PJ, Obarzanek E, Vollmer WM, et al.Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18-month results of a randomized trial. Ann Intern Med. 2006;144:485-495.
126. Jehn ML, Patt MR, Appel LJ, Miller ER 3rd. One year follow-up of overweight and obese hypertensive adults following intensive lifestyle therapy. J Hum Nutr Diet. 2006;19:349-354.
127. Lien LF, Brown AJ, Ard JD, et al.Effects of PREMIER lifestyle modifications on participants with and without the metabolic syndrome. Hypertension. 2007;50:609-616.
128. Blumenthal JA, Babyak MA, Hinderliter A, et al.Effects of the DASH diet alone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure: the ENCORE study. Arch Intern Med. 2010;170:126-135.
129. Gao SK, Fitzpatrick AL, Psaty B, et al.Suboptimal nutritional intake for hypertension control in 4 ethnic groups. Arch Intern Med. 2009;169:702-707.
130. Burke V, Beilin LJ, Cutt HE, et al.Effects of a lifestyle programme on ambulatory blood pressure and drug dosage in treated hypertensive patients: a randomized controlled trial. J Hypertens. 2005;23:1241-1249.
131. Sacks FM, Svetkey LP, Vollmer WM, et al.Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001;344:3-10.
132. Fujita T. Mineralocorticoid receptors, salt-sensitive hypertension, and metabolic syndrome. Hypertension. 2010;55:813-818.
133. Cook NR, Cutler JA, Obarzanek E, et al.Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ. 2007;334:885-888.
134. The Hypertension Prevention Trial: three-year effects of dietary changes on blood pressure. Hypertension Prevention Trial Research Group. Arch Intern Med. 1990;150:153-162.
135. Whelton PK, Kumanyika SK, Cook NR, et al.Efficacy of nonpharmacologic interventions in adults with high-normal blood pressure: results from phase 1 of the Trials of Hypertension Prevention. Trials of Hypertension Prevention Collaborative Research Group. Am J Clin Nutr. 1997;2(suppl):652S-660S.
136. Stevens VJ, Obarzanek E, Cook NR, et al.Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med. 2001;134:1-11.
137. Kumanyika SK, Cook NR, Cutler JA, et al.Sodium reduction for hypertension prevention in overweight adults: further results from the Trials of Hypertension Prevention Phase II. J Hum Hypertens. 2005;19:33-45.
138. Appel LJ, Espeland MA, Easter L, et al.Effects of reduced sodium intake on hypertension control in older individuals: results from the Trial of Nonpharmacologic Interventions in the Elderly (TONE). Arch Intern Med. 2001;161:685-693.
139. Thorogood A, Mottillo S, Shimony A, et al.Isolated aerobic exercise and weight loss: a systematic review and meta-analysis of randomized controlled trials. Am J Med. 2011;124:747-755.
140. Douketis JD, Macie C, Thabane L, Williamson DF. Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice. Int J Obes (Lond). 2005;29:1153-1167.
141. Fagard RH. Exercise is good for your blood pressure: effects of endurance training and resistance training. Clin Exp Pharmacol Physiol. 2006;33:853-856.
142. Cox KL, Puddey IB, Morton AR, et al.Exercise and weight control in sedentary overweight men: effects on clinic and ambulatory blood pressure. J Hypertens. 1996;14:779-790.
143. Cornelissen VA, Fagard RH, Coeckelberghs E, Vanhees L. Impact of resistance training on blood pressure and other cardiovascular risk factors: a meta-analysis of randomized, controlled trials. Hypertension. 2011;58:950-958.
144. Shaw K, Gennat H, O'Rourke P, Del Mar C. Exercise for overweight or obesity. Cochrane Database Syst Rev. 2006;CD003817.
145. Fogelholm M, Kukkonen-Harjula K. Does physical activity prevent weight gain - a systematic review. Obes Rev. 2000;1:95-111.
146. Jakicic JM. The effect of physical activity on body weight. Obesity (Silver Spring). 2009;17(suppl 3):S34-S38.
147. Proper KI, Singh AS, van Mechelen W, Chinapaw MJ. Sedentary behaviors and health outcomes among adults: a systematic review of prospective studies. Am J Prev Med. 2011;40:174-182.
148. Puddey IB, Beilin LJ. Alcohol is bad for blood pressure. Clin Exp Pharmacol Physiol. 2006;33:847-852.
149. Costanzo S, Di Castelnuovo A, Donati MB, et al.Wine, beer or spirit drinking in relation to fatal and non-fatal cardiovascular events: a meta-analysis. Eur J Epidemiol. 2011;26:833-850.
150. Sayon-Orea C, Martinez-Gonzalez MA, Bes-Rastrollo M. Alcohol consumption and body weight: a systematic review. Nutr Rev. 2011;69:419-431.
151. Puddey IB, Parker M, Beilin LJ, et al.Effects of alcohol and caloric restrictions on blood pressure and serum lipids in overweight men. Hypertension. 1992;20:533-541.
152. Canoy D, Wareham N, Luben R, et al.Cigarette smoking and fat distribution in 21, 828 British men and women: a population-based study. Obes Res. 2005;13:1466-1475.
153. Rhee MY, Na SH, Kim YK, et al.Acute effects of cigarette smoking on arterial stiffness and blood pressure in male smokers with hypertension. Am J Hypertens. 2007;20:637-641.
154. Simpson SA, Shaw C, McNamara R. What is the most effective way to maintain weight loss in adults?BMJ. 2011;343:d8042.
155. Van Dorsten B, Lindley EM. Cognitive and behavioral approaches in the treatment of obesity. Med Clin North Am. 2011;95:971-988.
156. Greaves CJ, Sheppard KE, Abraham C, et al.Systematic review of reviews of intervention components associated with increased effectiveness in dietary and physical activity interventions. BMC Public Health. 2011;11:119.
157. Svetkey LP, Stevens VJ, Brantley PJ, et al.Comparison of strategies for sustaining weight loss: the weight loss maintenance randomized controlled trial. JAMA. 2008;299:1139-1148.
158. Funk KL, Stevens VJ, Appel LJ, et al.Associations of internet website use with weight change in a long-term weight loss maintenance program. J Med Internet Res. 2010;12:e29.
159. Tuomilehto J, Lindstrom J, Eriksson JG, et al.Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350.
160. Knowler WC, Barrett-Connor E, Fowler SE, et al.Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
161. McCullough ML, Patel AV, Kushi LH, et al.Following cancer prevention guidelines reduces risk of cancer, cardiovascular disease, and all-cause mortality. Cancer Epidemiol Biomark Prev. 2011;20:1089-1097.
162. Ketola E, Sipila R, Makela M. Effectiveness of individual lifestyle interventions in reducing cardiovascular disease and risk factors. Ann Med. 2000;32:239-251.
163. Angermayr L, Melchart D, Linde K. Multifactorial lifestyle interventions in the primary and secondary prevention of cardiovascular disease and type 2 diabetes mellitus - a systematic review of randomized controlled trials. Ann Behav Med. 2010;40:49-64.
164. Ebrahim S, Taylor F, Ward K, et al.Multiple risk factor interventions for primary prevention of coronary heart disease. Cochrane Database Syst Rev. 2011;CD001561.
165. Mancia G, De Backer G, Dominiczak A, et al.Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and or the European Society of Cardiology (ESC). Eur Heart J. 2007;28:1462-1536.
166. Moore LL, Visioni AJ, Qureshi MM, et al.Weight loss in overweight adults and the long-term risk of hypertension: the Framingham study. Arch Intern Med. 2005;165:1298-1303.
167. Allcock DM, Sowers JR. Best strategies for hypertension management in type 2 diabetes and obesity. Curr Diab Rep. 2010;10:139-144.
168. Jandeleit-Dahm KA, Tikellis C, Reid CM, et al.Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens. 2005;23:463-473.
169. Sharma AM, Engeli S. The role of renin-angiotensin system blockade in the management of hypertension associated with the cardiometabolic syndrome. J Cardiometab Syndr. 2006;1:29-35.
170. Lindholm LH, Ibsen H, Borch-Johnsen K, et al.Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens. 2002;20:1879-1886.
171. Gupta AK, Dahlof B, Dobson J, et al.Determinants of new-onset diabetes among 19, 257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm and the relative influence of antihypertensive medication. Diabetes Care. 2008;31:982-988.
172. Lardizabal JA, Deedwania PC. The role of renin-angiotensin agents in altering the natural history of type 2 diabetes mellitus. Curr Cardiol Rep. 2010;12:464-471.
173. Wing LM, Reid CM, Ryan P, et al.A comparison of outcomes with angiotensin-converting - enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583-592.
174. Redon J, Cifkova R, Laurent S, et al.The metabolic syndrome in hypertension: European Society of Hypertension position statement. J Hypertens. 2008;26:1891-1900.
175. Kjeldsen SE, Julius S, Mancia G, et al.Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J Hypertens. 2006;24:1405-1412.
176. Grimm C, Koberlein J, Wiosna W, et al.New-onset diabetes and antihypertensive treatment. GMS Health Technol Assess. 2010;6:Doc03.
177. National High Blood Pressure Education Program. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda, MD: National Heart, Lung and Blood Institute (US); 2004;Report No.: 04-5230.
178. Lee P, Kengne AP, Greenfield JR, et al.Metabolic sequelae of beta-blocker therapy: weighing in on the obesity epidemic?Int J Obes (Lond). 2011;35:1395-1403.
179. Messerli FH, Bell DS, Fonseca V, et al.Body weight changes with beta-blocker use: results from GEMINI. Am J Med. 2007;120:610-615.
180. Sharma AM, Pischon T, Hardt S, et al.Hypothesis: beta-adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension. 2001;37:250-254.
181. Manrique C, Whaley-Connell A, Sowers JR. Nebivolol in obese and non-obese hypertensive patients. J Clin Hypertens (Greenwich). 2009;11:309-315.
182. NHLBI Obesity Education Initiative Working Group. The Practical Guide: Identification, Evaluation and Treatment of Overweight and Obesity in Adults. Bethesda, MD: NIH Publication 00-4084; 2000.
183. Lawrence CB, Turnbull AV, Rothwell NJ. Hypothalamic control of feeding. Curr Opin Neurobiol. 1999;9:778-783.
184. Garfield AS, Lam DD, Marston OJ, et al.Role of central melanocortin pathways in energy homeostasis. Trends Endocrinol Metab. 2009;20:203-215.
185. van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM, et al.Cold-activated brown adipose tissue in healthy men. N Engl J Med. 2009;360:1500-1508.
186. Bostrom P, Wu J, Jedrychowski MP, et al.A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481:463-468.
187. Bordicchia M, Liu D, Amri EZ, et al.Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J Clin Invest. 2012;122:1022-1036.
188. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155-161.
189. Genentech USA, Inc. Xenical (Orlistat) Package Insert. South San Francisco, CA: Genentech USA, Inc; 2010.
190. Over-the-counter weight loss with orlistat?Drug Ther Bull. 2009;47:125-127.
191. Hauptman J, Lucas C, Boldrin MN, et al.Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med. 2000;9:160-167.
192. Rossner S, Sjostrom L, Noack R, et al.Weight loss, weight maintenance, and improved cardiovascular risk factors after 2years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res. 2000;8:49-61.
193. Kaplan LM. Pharmacological therapies for obesity. Gastroenterol Clin North Am. 2005;34:91-104.
194. Li Z, Maglione M, Tu W, et al.Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005;142:532-546.
195. Bray GA, Ryan DH. Drug treatment of the overweight patient. Gastroenterology. 2007;132:2239-2252.
196. Haddock CK, Poston WS, Dill PL, et al.Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord. 2002;26:262-273.
197. Hendricks EJ, Greenway FL, Westman EC, Gupta AK. Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity. Obesity (Silver Spring). 2011;19:2351-2360.
198. Bristol-Myers Squibb Company, Glucophage (metformin) Package Insert. Uxbridge, UK: Bristol-Myers Squibb Company; 2009.
199. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med. 1995;333:541-549.
200. Robinson AC, Burke J, Robinson S, et al.The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control. Diabetes Care. 1998;21:701-705.
201. Amylin Pharmaceuticals and Eli Lilly & Company. Byetta Package Insert. Cincinnati, OH: Amylin Pharmaceuticals and Eli Lilly & Company; 2010.
202. Moretto TJ, Milton DR, Ridge TD, et al.Efficacy and tolerability of exenatide monotherapy over 24weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2008;30:1448-1460.
203. DeFronzo RA, Ratner RE, Han J, et al.Effects of exenatide (exendin-4) on glycemic control and weight over 30weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28:1092-1100.
204. Buse JB, Henry RR, Han J, et al.Effects of exenatide (exendin-4) on glycemic control over 30weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628-2635.
205. Kendall DM, Riddle MC, Rosenstock J, et al.Effects of exenatide (exendin-4) on glycemic control over 30weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28:1083-1091.
206. Blonde L, Klein EJ, Han J, et al.Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab. 2006;8:436-447.
207. Buse JB, Klonoff DC, Nielsen LL, et al.Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther. 2007;29:139-153.
208. Horton ES, Silberman C, Davis KL, Berria R. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes Care. 2010;33:1759-1765.
209. Amylin Pharmacueticals. Symlin (pramlintide) Package Insert. 812003-CC. Cincinnati, OH: Amylin Pharmacueticals; 2008.
210. Ratner RE, Dickey R, Fineman M, et al.Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med. 2004;21:1204-1212.
211. Younk LM, Mikeladze M, Davis SN. Pramlintide and the treatment of diabetes: a review of the data since its introduction. Expert Opin Pharmacother. 2011;12:1439-1451.
212. Hollander PA, Levy P, Fineman MS, et al.Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care. 2003;26:784-790.
213. Aronne L, Fujioka K, Aroda V, et al.Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab. 2007;92:2977-2983.
214. Aronne LJ, Isoldi KK, Roarke DT. The Johns Hopkins University Textbook of Dyslipidemia Chapter 24: Therapeutic Options for Modifying Obesity and Cardiometabolic Risk Factors. 288.
215. Smith SR, Aronne LJ, Burns CM, et al.Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care. 2008;31:1816-1823.
216. Gadde KM, Allison DB, Ryan DH, et al.Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:1341-1352.
217. Greenway FL, Fujioka K, Plodkowski RA, et al.Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376:595-605.
218. Rubino F, R'Bibo SL, del Genio F, et al.Metabolic surgery: the role of the gastrointestinal tract in diabetes mellitus. Nat Rev Endocrinol. 2010;6:102-109.
219. Buchwald H, Avidor Y, Braunwald E, et al.Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292:1724-1737.
220. Sjostrom L, Lindroos AK, Peltonen M, et al.Lifestyle, diabetes, and cardiovascular risk factors 10years after bariatric surgery. N Engl J Med. 2004;351:2683-2693.
221. Delling L, Karason K, Olbers T, et al.Feasibility of bariatric surgery as a strategy for secondary prevention in cardiovascular disease: a report from the Swedish obese subjects trial. J Obes. 2010;2010:102341.
222. Saxe JS. Promoting healthy lifestyles and decreasing childhood obesity: increasing physician effectiveness through advocacy. Ann Fam Med. 2011;9:546-548.